Scholars@Duke

The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy

Publication ,  Journal Article
McAdam, LC; Mayo, AL; Alman, BA; Biggar, WD
Published in: Acta Myologica
May 1, 2012

Deflazacort is the most commonly prescribed corticosteroid for the treatment of Duchenne muscular dystrophy in Canada. We review the long term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival. Common side effects in both cohorts include weight gain, decreased height and cataract formation. The Canadian experience supports the use of deflazacort in treating boys with Duchenne muscular dystrophy.

Duke Scholars

Benjamin Aaron Alman
Author Benjamin Aaron Alman Orthopaedic Surgery

Published In

Acta Myologica

ISSN

1128-2460

Publication Date

May 1, 2012

Volume

31

Issue

MAY

Start / End Page

16 / 20

Related Subject Headings

  • Neurology & Neurosurgery
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McAdam, L. C., Mayo, A. L., Alman, B. A., & Biggar, W. D. (2012). The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy. Acta Myologica, 31(MAY), 16–20.
McAdam, L. C., A. L. Mayo, B. A. Alman, and W. D. Biggar. “The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy.” Acta Myologica 31, no. MAY (May 1, 2012): 16–20.
McAdam LC, Mayo AL, Alman BA, Biggar WD. The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy. Acta Myologica. 2012 May 1;31(MAY):16–20.
McAdam, L. C., et al. “The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy.” Acta Myologica, vol. 31, no. MAY, May 2012, pp. 16–20.
McAdam LC, Mayo AL, Alman BA, Biggar WD. The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy. Acta Myologica. 2012 May 1;31(MAY):16–20.

Published In

Acta Myologica

ISSN

1128-2460

Publication Date

May 1, 2012

Volume

31

Issue

MAY

Start / End Page

16 / 20

Related Subject Headings

  • Neurology & Neurosurgery
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology